Dr. Samuel Silver, MD – Ann Arbor, MI
Matthew Elliott
Updated on January 10, 2026
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Manisha Balwani, M.D., Eliane Sardh, M.D., Ph.D., Paolo Ventura, M.D., Paula Aguilera Peiró, M.D., David C. Rees, F.R.C.P., Ulrich Stölzel, M.D., D. Montgomery Bissell..., New England Journal of Medicine, 6/11/2020The devil’s in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda
B Sunkara, D Roofeh, S Silver, T LeBleu Pearson, M Ettel and WJ McCune, Lupus (2018) 27, 1383–1386, 2018Change in rate-determining steps for a simple carbonyl addition reaction. Kinetically significant proton transfer step in acid-catalyzed O-methyloxime formation.
Silver SM and Sayer JM, J Amer Chem Soc
